person · Reporting owner

JAEGER WILFRED E

Disclosed activity across 4 companies

Tapewire entity: 112995
SEC CIK: 0001190474

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
NEVRO CORPNVRO · Entity 12422	Director	May 21, 2020	May 26, 2020
Neuronetics, Inc.STIM · Entity 6248	Director	May 25, 2023	May 31, 2023
TALPHERA, INC.ACRX · Entity 7102	10% owner	May 21, 2018	May 23, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

NEVRO CORP

Report date May 21, 2020 · Filed May 26, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	9,592	Reported balance After 2020-05-21 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2020-05-21 · Grant · Acquired 1,376 · Balance 9,592 F1: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 21, 2020 or (ii) the next Annual Meeting following May 21, 2020, subject to the Reporting Person's continued service to the issuer. F2: Includes 1,376 restricted stock units.
Common StockSEC Table I · non-derivative	IndirectSee footnote	25,341	Reported balance Holding disclosure · report date 2020-05-21 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 25,341 F3: Shares are held by Wilfred E. Jaeger and Judith F. Jaeger, TTEES of the Jaeger Family Trust DTD 4/30/99.
Common StockSEC Table I · non-derivative	IndirectSee footnote	3,106	Reported balance Holding disclosure · report date 2020-05-21 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 3,106 F4: Shares are held by Nicholas Graham Jaeger 2002 Irrevocable Trust U/D/T 04/23/2002.
Common StockSEC Table I · non-derivative	IndirectSee footnote	3,106	Reported balance Holding disclosure · report date 2020-05-21 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 3,106 F5: Shares are held by Emma Louise Jaeger 2002 Irrevocable Trust U/D/T 04/23/2002.

Filing footnotes · ownership attribution and instrument terms

F1: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 21, 2020 or (ii) the next Annual Meeting following May 21, 2020, subject to the Reporting Person's continued service to the issuer.

F2: Includes 1,376 restricted stock units.

F3: Shares are held by Wilfred E. Jaeger and Judith F. Jaeger, TTEES of the Jaeger Family Trust DTD 4/30/99.

F4: Shares are held by Nicholas Graham Jaeger 2002 Irrevocable Trust U/D/T 04/23/2002.

F5: Shares are held by Emma Louise Jaeger 2002 Irrevocable Trust U/D/T 04/23/2002.

Neuronetics, Inc.

Report date May 25, 2023 · Filed May 31, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	138,563	Reported balance After 2023-05-25 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2023-05-25 · Grant · Acquired 36,364 · Balance 138,563 F1: Represents a restricted stock unit ("RSU") award that vests on the earlier of (a) May 23, 2024, or (b) the reporting person's Board-approved separation of service from the Issuer, in each case subject to continuous service of the reporting person through such date. F2: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F3: Reflects an adjustment to total holdings to include 12 RSUs inadvertently excluded in prior reports.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.43 · Expires 2029-05-27	Direct	16,102	Reported balance Holding disclosure · report date 2023-05-25 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance 16,102 F4: The option shall vest on the earlier of (a) May 28, 2029, and (b) the Company's next annual meeting of stockholders, in each case subject to continuous service of the Reporting Person through such date. F5: Reflects an adjustment to total holdings to exclude 12 options inadvertently included in the reporting person's May 30, 2019 report.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a restricted stock unit ("RSU") award that vests on the earlier of (a) May 23, 2024, or (b) the reporting person's Board-approved separation of service from the Issuer, in each case subject to continuous service of the reporting person through such date.

F2: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F3: Reflects an adjustment to total holdings to include 12 RSUs inadvertently excluded in prior reports.

F4: The option shall vest on the earlier of (a) May 28, 2029, and (b) the Company's next annual meeting of stockholders, in each case subject to continuous service of the Reporting Person through such date.

F5: Reflects an adjustment to total holdings to exclude 12 options inadvertently included in the reporting person's May 30, 2019 report.

TALPHERA, INC.

Report date May 21, 2018 · Filed May 23, 2018

Jointly reported with WAN MARK A, THREE ARCH PARTNERS IV LP, THREE ARCH PARTNERS III LP, THREE ARCH ASSOCIATES IV LP, THREE ARCH ASSOCIATES III LP

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2018-05-21 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2018-05-21 · Other · Disposed 3,347,357 · Balance 0 F1: The shares are owned directly by Three Arch Partners III, L.P. ("TAP III"). Three Arch Management III, L.L.C. ("TAM III"), the general partner of TAP III, had sole voting and dispositive power with respect to the securities held by TAP III. Mark A. Wan and Wilfred Jaeger, the managing members of TAM III, shared the voting and dispositive power with respect to the shares held by TAP III. Such persons and entities disclaim beneficial ownership of the shares held by TAP III except to the extent of any pecuniary interest therein. See Explanation of Responses #5 for more information. F5: On May 21, 2018, the TAP III, TAP IV, TAA III and TAA IV (the "Affiliated Entities") and certain other affiliates of the Affiliated Entities and Leerink Revelation Healthcare Fund I, L.P., Industry Ventures Secondary VIII, L.P. and Kline Hill Partners Fund II LP (the "Purchasers") entered into a purchase agreement (the "Purchase Agreement") pursuant to which the Affiliated Entities agreed to a sale to the Purchasers (the "Portfolio Sale") of a portfolio of assets held by the Affiliated Entities consisting of the securities of private and public companies, including the 9,367,041 shares of Common Stock (the "AcelRx Shares") of AcelRx Pharmaceuticals, Inc. (the "Issuer") and other investment interests. The transfer of the AcelRx Shares and the securities of another portfolio asset (such securities together with the AcelRx Shares, the "Initial Closing Securities") was consummated at an initial closing on May 21, 2018 to the Purchasers. F6: (Continued From Footenote 5) The Portfolio Sale was undertaken for portfolio management purposes in connection with the imminent expiration of the terms of the Affiliated Entities under their respective governing agreements, as the Affiliated Entities were initially formed between 1999 and 2004 with initially contemplated terms of ten years. The Portfolio Sale was undertaken as a result of the imminent dissolution of the Affiliated Entities due to the upcoming expiration of the terms under the governing agreements. The Portfolio Sale is not being undertaken as a result of an adverse change in the Affiliated Entities' views on the prospects of the Issuer, or its businesses, management or directors. Wan, a director of the Issuer and affiliate of the Affiliated Entities, will continue serving as a member of the Issuer's Board of Directors after the Portfolio Sale. F7: (Continued From Footenote 6) The aggregate purchase price to be paid by the Purchasers in the Portfolio Sale is $30 million in up front consideration, plus a residual amount calculated based on, among other things, the trading price of the AcelRx Shares and certain other securities as of the end of calendar year 2018, up to a maximum aggregate amount of $12.5 million in additional consideration (the "Residual Consideration"). The Initial Closing Securities sold by the Affiliated Entities in the Portfolio Sale were priced on an aggregate basis, for total consideration in the range of $25 million to $37.5 million, depending upon the amount of Residual Consideration eventually paid. Because the Initial Closing Securities sold by the Affiliated Entities in the Portfolio Sale were price on an aggregate basis, a price per share was not separately determined for the AcelRx Shares.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2018-05-21 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2018-05-21 · Other · Disposed 179,962 · Balance 0 F2: The shares are owned directly by Three Arch Associates III, L.P. ("TAA III"). TAM III, the general partner of TAA III, had sole voting and dispositive power with respect to the securities held by TAA III. Mark A. Wan and Wilfred Jaeger, the managing members of TAM III, shared the voting and dispositive power with respect to the shares held by TAA III. Such persons and entities disclaim beneficial ownership of the shares held by TAA III except to the extent of any pecuniary interest therein. See Explanation of Responses #5 for more information. F5: On May 21, 2018, the TAP III, TAP IV, TAA III and TAA IV (the "Affiliated Entities") and certain other affiliates of the Affiliated Entities and Leerink Revelation Healthcare Fund I, L.P., Industry Ventures Secondary VIII, L.P. and Kline Hill Partners Fund II LP (the "Purchasers") entered into a purchase agreement (the "Purchase Agreement") pursuant to which the Affiliated Entities agreed to a sale to the Purchasers (the "Portfolio Sale") of a portfolio of assets held by the Affiliated Entities consisting of the securities of private and public companies, including the 9,367,041 shares of Common Stock (the "AcelRx Shares") of AcelRx Pharmaceuticals, Inc. (the "Issuer") and other investment interests. The transfer of the AcelRx Shares and the securities of another portfolio asset (such securities together with the AcelRx Shares, the "Initial Closing Securities") was consummated at an initial closing on May 21, 2018 to the Purchasers. F6: (Continued From Footenote 5) The Portfolio Sale was undertaken for portfolio management purposes in connection with the imminent expiration of the terms of the Affiliated Entities under their respective governing agreements, as the Affiliated Entities were initially formed between 1999 and 2004 with initially contemplated terms of ten years. The Portfolio Sale was undertaken as a result of the imminent dissolution of the Affiliated Entities due to the upcoming expiration of the terms under the governing agreements. The Portfolio Sale is not being undertaken as a result of an adverse change in the Affiliated Entities' views on the prospects of the Issuer, or its businesses, management or directors. Wan, a director of the Issuer and affiliate of the Affiliated Entities, will continue serving as a member of the Issuer's Board of Directors after the Portfolio Sale. F7: (Continued From Footenote 6) The aggregate purchase price to be paid by the Purchasers in the Portfolio Sale is $30 million in up front consideration, plus a residual amount calculated based on, among other things, the trading price of the AcelRx Shares and certain other securities as of the end of calendar year 2018, up to a maximum aggregate amount of $12.5 million in additional consideration (the "Residual Consideration"). The Initial Closing Securities sold by the Affiliated Entities in the Portfolio Sale were priced on an aggregate basis, for total consideration in the range of $25 million to $37.5 million, depending upon the amount of Residual Consideration eventually paid. Because the Initial Closing Securities sold by the Affiliated Entities in the Portfolio Sale were price on an aggregate basis, a price per share was not separately determined for the AcelRx Shares.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2018-05-21 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2018-05-21 · Other · Disposed 5,713,569 · Balance 0 F3: The shares are owned directly by Three Arch Partners IV, L.P. ("TAP IV"). Three Arch Management IV, L.L.C. ("TAM IV"), the general partner of TAP IV, had sole voting and dispositive power with respect to the securities held by TAP IV. Mark A. Wan and Wilfred Jaeger, the managing members of TAM IV, shared the voting and dispositive power with respect to the shares held by TAP IV. Such persons and entities disclaim beneficial ownership of the shares held by TAP IV except to the extent of any pecuniary interest therein. See Explanation of Responses #5 for more information. F5: On May 21, 2018, the TAP III, TAP IV, TAA III and TAA IV (the "Affiliated Entities") and certain other affiliates of the Affiliated Entities and Leerink Revelation Healthcare Fund I, L.P., Industry Ventures Secondary VIII, L.P. and Kline Hill Partners Fund II LP (the "Purchasers") entered into a purchase agreement (the "Purchase Agreement") pursuant to which the Affiliated Entities agreed to a sale to the Purchasers (the "Portfolio Sale") of a portfolio of assets held by the Affiliated Entities consisting of the securities of private and public companies, including the 9,367,041 shares of Common Stock (the "AcelRx Shares") of AcelRx Pharmaceuticals, Inc. (the "Issuer") and other investment interests. The transfer of the AcelRx Shares and the securities of another portfolio asset (such securities together with the AcelRx Shares, the "Initial Closing Securities") was consummated at an initial closing on May 21, 2018 to the Purchasers. F6: (Continued From Footenote 5) The Portfolio Sale was undertaken for portfolio management purposes in connection with the imminent expiration of the terms of the Affiliated Entities under their respective governing agreements, as the Affiliated Entities were initially formed between 1999 and 2004 with initially contemplated terms of ten years. The Portfolio Sale was undertaken as a result of the imminent dissolution of the Affiliated Entities due to the upcoming expiration of the terms under the governing agreements. The Portfolio Sale is not being undertaken as a result of an adverse change in the Affiliated Entities' views on the prospects of the Issuer, or its businesses, management or directors. Wan, a director of the Issuer and affiliate of the Affiliated Entities, will continue serving as a member of the Issuer's Board of Directors after the Portfolio Sale. F7: (Continued From Footenote 6) The aggregate purchase price to be paid by the Purchasers in the Portfolio Sale is $30 million in up front consideration, plus a residual amount calculated based on, among other things, the trading price of the AcelRx Shares and certain other securities as of the end of calendar year 2018, up to a maximum aggregate amount of $12.5 million in additional consideration (the "Residual Consideration"). The Initial Closing Securities sold by the Affiliated Entities in the Portfolio Sale were priced on an aggregate basis, for total consideration in the range of $25 million to $37.5 million, depending upon the amount of Residual Consideration eventually paid. Because the Initial Closing Securities sold by the Affiliated Entities in the Portfolio Sale were price on an aggregate basis, a price per share was not separately determined for the AcelRx Shares.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2018-05-21 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2018-05-21 · Other · Disposed 126,153 · Balance 0 F4: The shares are owned directly by Three Arch Associates IV, L.P. ("TAA IV"). TAM IV, the general partner of TAA IV, had sole voting and dispositive power with respect to the securities held by TAA IV. Mark A. Wan and Wilfred Jaeger, the managing members of TAM IV, shared the voting and dispositive power with respect to the shares held by TAA IV. Such persons and entities disclaim beneficial ownership of the shares held by TAA IV except to the extent of any pecuniary interest therein. See Explanation of Responses #5 for more information. F5: On May 21, 2018, the TAP III, TAP IV, TAA III and TAA IV (the "Affiliated Entities") and certain other affiliates of the Affiliated Entities and Leerink Revelation Healthcare Fund I, L.P., Industry Ventures Secondary VIII, L.P. and Kline Hill Partners Fund II LP (the "Purchasers") entered into a purchase agreement (the "Purchase Agreement") pursuant to which the Affiliated Entities agreed to a sale to the Purchasers (the "Portfolio Sale") of a portfolio of assets held by the Affiliated Entities consisting of the securities of private and public companies, including the 9,367,041 shares of Common Stock (the "AcelRx Shares") of AcelRx Pharmaceuticals, Inc. (the "Issuer") and other investment interests. The transfer of the AcelRx Shares and the securities of another portfolio asset (such securities together with the AcelRx Shares, the "Initial Closing Securities") was consummated at an initial closing on May 21, 2018 to the Purchasers. F6: (Continued From Footenote 5) The Portfolio Sale was undertaken for portfolio management purposes in connection with the imminent expiration of the terms of the Affiliated Entities under their respective governing agreements, as the Affiliated Entities were initially formed between 1999 and 2004 with initially contemplated terms of ten years. The Portfolio Sale was undertaken as a result of the imminent dissolution of the Affiliated Entities due to the upcoming expiration of the terms under the governing agreements. The Portfolio Sale is not being undertaken as a result of an adverse change in the Affiliated Entities' views on the prospects of the Issuer, or its businesses, management or directors. Wan, a director of the Issuer and affiliate of the Affiliated Entities, will continue serving as a member of the Issuer's Board of Directors after the Portfolio Sale. F7: (Continued From Footenote 6) The aggregate purchase price to be paid by the Purchasers in the Portfolio Sale is $30 million in up front consideration, plus a residual amount calculated based on, among other things, the trading price of the AcelRx Shares and certain other securities as of the end of calendar year 2018, up to a maximum aggregate amount of $12.5 million in additional consideration (the "Residual Consideration"). The Initial Closing Securities sold by the Affiliated Entities in the Portfolio Sale were priced on an aggregate basis, for total consideration in the range of $25 million to $37.5 million, depending upon the amount of Residual Consideration eventually paid. Because the Initial Closing Securities sold by the Affiliated Entities in the Portfolio Sale were price on an aggregate basis, a price per share was not separately determined for the AcelRx Shares.

Filing footnotes · ownership attribution and instrument terms

F1: The shares are owned directly by Three Arch Partners III, L.P. ("TAP III"). Three Arch Management III, L.L.C. ("TAM III"), the general partner of TAP III, had sole voting and dispositive power with respect to the securities held by TAP III. Mark A. Wan and Wilfred Jaeger, the managing members of TAM III, shared the voting and dispositive power with respect to the shares held by TAP III. Such persons and entities disclaim beneficial ownership of the shares held by TAP III except to the extent of any pecuniary interest therein. See Explanation of Responses #5 for more information.

F2: The shares are owned directly by Three Arch Associates III, L.P. ("TAA III"). TAM III, the general partner of TAA III, had sole voting and dispositive power with respect to the securities held by TAA III. Mark A. Wan and Wilfred Jaeger, the managing members of TAM III, shared the voting and dispositive power with respect to the shares held by TAA III. Such persons and entities disclaim beneficial ownership of the shares held by TAA III except to the extent of any pecuniary interest therein. See Explanation of Responses #5 for more information.

F3: The shares are owned directly by Three Arch Partners IV, L.P. ("TAP IV"). Three Arch Management IV, L.L.C. ("TAM IV"), the general partner of TAP IV, had sole voting and dispositive power with respect to the securities held by TAP IV. Mark A. Wan and Wilfred Jaeger, the managing members of TAM IV, shared the voting and dispositive power with respect to the shares held by TAP IV. Such persons and entities disclaim beneficial ownership of the shares held by TAP IV except to the extent of any pecuniary interest therein. See Explanation of Responses #5 for more information.

F4: The shares are owned directly by Three Arch Associates IV, L.P. ("TAA IV"). TAM IV, the general partner of TAA IV, had sole voting and dispositive power with respect to the securities held by TAA IV. Mark A. Wan and Wilfred Jaeger, the managing members of TAM IV, shared the voting and dispositive power with respect to the shares held by TAA IV. Such persons and entities disclaim beneficial ownership of the shares held by TAA IV except to the extent of any pecuniary interest therein. See Explanation of Responses #5 for more information.

F5: On May 21, 2018, the TAP III, TAP IV, TAA III and TAA IV (the "Affiliated Entities") and certain other affiliates of the Affiliated Entities and Leerink Revelation Healthcare Fund I, L.P., Industry Ventures Secondary VIII, L.P. and Kline Hill Partners Fund II LP (the "Purchasers") entered into a purchase agreement (the "Purchase Agreement") pursuant to which the Affiliated Entities agreed to a sale to the Purchasers (the "Portfolio Sale") of a portfolio of assets held by the Affiliated Entities consisting of the securities of private and public companies, including the 9,367,041 shares of Common Stock (the "AcelRx Shares") of AcelRx Pharmaceuticals, Inc. (the "Issuer") and other investment interests. The transfer of the AcelRx Shares and the securities of another portfolio asset (such securities together with the AcelRx Shares, the "Initial Closing Securities") was consummated at an initial closing on May 21, 2018 to the Purchasers.

F6: (Continued From Footenote 5) The Portfolio Sale was undertaken for portfolio management purposes in connection with the imminent expiration of the terms of the Affiliated Entities under their respective governing agreements, as the Affiliated Entities were initially formed between 1999 and 2004 with initially contemplated terms of ten years. The Portfolio Sale was undertaken as a result of the imminent dissolution of the Affiliated Entities due to the upcoming expiration of the terms under the governing agreements. The Portfolio Sale is not being undertaken as a result of an adverse change in the Affiliated Entities' views on the prospects of the Issuer, or its businesses, management or directors. Wan, a director of the Issuer and affiliate of the Affiliated Entities, will continue serving as a member of the Issuer's Board of Directors after the Portfolio Sale.

F7: (Continued From Footenote 6) The aggregate purchase price to be paid by the Purchasers in the Portfolio Sale is $30 million in up front consideration, plus a residual amount calculated based on, among other things, the trading price of the AcelRx Shares and certain other securities as of the end of calendar year 2018, up to a maximum aggregate amount of $12.5 million in additional consideration (the "Residual Consideration"). The Initial Closing Securities sold by the Affiliated Entities in the Portfolio Sale were priced on an aggregate basis, for total consideration in the range of $25 million to $37.5 million, depending upon the amount of Residual Consideration eventually paid. Because the Initial Closing Securities sold by the Affiliated Entities in the Portfolio Sale were price on an aggregate basis, a price per share was not separately determined for the AcelRx Shares.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

CONCERT PHARMACEUTICALS, INC.

Report date March 06, 2023 · Filed March 06, 2023

Section 16 reporting ended · disclosed 2023-03-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-03-06 transaction · row 1 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 1 · 2023-03-06 · Other · Disposed 5,125 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 19, 2023, by and among Concert Pharmaceuticals, Inc. (the "Issuer"), Sun Pharmaceutical Industries Ltd. ("Parent") and Foliage Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of March 6, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.00 in cash (the "Cash Amount"), plus one non-tradeable contingent value right (a "CVR," and together with the Cash Amount, the "Per Share Consideration"), which represents the right to receive contingent payments of up to $3.50 per Share, in cash, (continued in Footnote 2) F2: in the aggregate, upon the achievement of certain milestones (such applicable payment, each, a "Milestone Payment") prior to December 31, 2029, subject to any applicable withholding of taxes and without interest.
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-03-06 transaction · row 2 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 2 · 2023-03-06 · Disposition to issuer · Disposed 16,400 · Balance 0 F3: This line item represents unvested time-based restricted stock units with respect to the Issuer's common stock ("RSUs") held by the Reporting Person. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSU that was outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive, for each Share underlying such RSU, the Per Share Consideration, subject to withholding of applicable taxes and without interest.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.42 · Expires 2025-06-10	Direct	Reported balance After 2023-03-06 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-03-06 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 5) F5: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.96 · Expires 2026-06-08	Direct	Reported balance After 2023-03-06 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-03-06 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 5) F5: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.29 · Expires 2027-06-14	Direct	Reported balance After 2023-03-06 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-03-06 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 5) F5: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.59 · Expires 2028-06-13	Direct	Reported balance After 2023-03-06 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-03-06 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 5) F5: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.02 · Expires 2029-06-12	Direct	Reported balance After 2023-03-06 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2023-03-06 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 5) F5: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.16 · Expires 2030-06-10	Direct	Reported balance After 2023-03-06 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2023-03-06 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 5) F5: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.26 · Expires 2031-06-09	Direct	Reported balance After 2023-03-06 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2023-03-06 · Disposition to issuer · Disposed 10,250 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 5) F5: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 19, 2023, by and among Concert Pharmaceuticals, Inc. (the "Issuer"), Sun Pharmaceutical Industries Ltd. ("Parent") and Foliage Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of March 6, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.00 in cash (the "Cash Amount"), plus one non-tradeable contingent value right (a "CVR," and together with the Cash Amount, the "Per Share Consideration"), which represents the right to receive contingent payments of up to $3.50 per Share, in cash, (continued in Footnote 2)

F2: in the aggregate, upon the achievement of certain milestones (such applicable payment, each, a "Milestone Payment") prior to December 31, 2029, subject to any applicable withholding of taxes and without interest.

F3: This line item represents unvested time-based restricted stock units with respect to the Issuer's common stock ("RSUs") held by the Reporting Person. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSU that was outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive, for each Share underlying such RSU, the Per Share Consideration, subject to withholding of applicable taxes and without interest.

F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 5)

F5: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 28, 2018 Filed Mar 1, 2018 20:12 UTC	NEVRO CORP NVRO · Entity 12422	SaleCommon Stock	7,844	$83.09	$651,790.90	Disclosure SEC source: 0001209191-18-015284 · doc4.xml · nonDerivative · entry 5 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 673,798 F5 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $83.00 to $83.25, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · ownership.nature: Shares are held by Three Arch Partners IV, L.P. ("TAP IV"). Three Arch Management IV, L.L.C. ("TAM IV"), the general partner of TAP IV, has sole voting and dispositive power with respect to the securities held by TAP IV. Mark A. Wan and Wilfred E. Jaeger, the managing members of TAM IV, share the voting and dispositive power with respect to the shares held by TAP IV. Such persons and entities disclaim beneficial ownership of the shares held by TAP IV except to the extent of any pecuniary interest therein. Read SEC document
February 27, 2018 Filed Mar 1, 2018 20:12 UTC	NEVRO CORP NVRO · Entity 12422	SaleCommon Stock	286	$83.20	$23,794.60	Disclosure SEC source: 0001209191-18-015284 · doc4.xml · nonDerivative · entry 4 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 15,051 F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $83.00 to $83.74, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: Shares are held by Three Arch Associates IV, L.P. ("TAA IV"). TAM IV, the general partner of TAA IV, has sole voting and dispositive power with respect to the securities held by TAA IV. Mark A. Wan and Wilfred E. Jaeger, the managing members of TAM IV, share the voting and dispositive power with respect to the shares held by TAA IV. Such persons and entities disclaim beneficial ownership of the shares held by TAA IV except to the extent of any pecuniary interest therein. Read SEC document
February 27, 2018 Filed Mar 1, 2018 20:12 UTC	NEVRO CORP NVRO · Entity 12422	SaleCommon Stock	12,972	$83.20	$1,079,243.16	Disclosure SEC source: 0001209191-18-015284 · doc4.xml · nonDerivative · entry 3 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 681,642 F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $83.00 to $83.74, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · ownership.nature: Shares are held by Three Arch Partners IV, L.P. ("TAP IV"). Three Arch Management IV, L.L.C. ("TAM IV"), the general partner of TAP IV, has sole voting and dispositive power with respect to the securities held by TAP IV. Mark A. Wan and Wilfred E. Jaeger, the managing members of TAM IV, share the voting and dispositive power with respect to the shares held by TAP IV. Such persons and entities disclaim beneficial ownership of the shares held by TAP IV except to the extent of any pecuniary interest therein. Read SEC document
February 27, 2018 Filed Mar 1, 2018 20:12 UTC	NEVRO CORP NVRO · Entity 12422	SaleCommon Stock	26	$84.17	$2,188.49	Disclosure SEC source: 0001209191-18-015284 · doc4.xml · nonDerivative · entry 2 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 15,337 F1 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $84.00 to $84.35, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: Shares are held by Three Arch Associates IV, L.P. ("TAA IV"). TAM IV, the general partner of TAA IV, has sole voting and dispositive power with respect to the securities held by TAA IV. Mark A. Wan and Wilfred E. Jaeger, the managing members of TAM IV, share the voting and dispositive power with respect to the shares held by TAA IV. Such persons and entities disclaim beneficial ownership of the shares held by TAA IV except to the extent of any pecuniary interest therein. Read SEC document
February 27, 2018 Filed Mar 1, 2018 20:12 UTC	NEVRO CORP NVRO · Entity 12422	SaleCommon Stock	1,174	$84.17	$98,818.52	Disclosure SEC source: 0001209191-18-015284 · doc4.xml · nonDerivative · entry 1 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 694,614 F1 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $84.00 to $84.35, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · ownership.nature: Shares are held by Three Arch Partners IV, L.P. ("TAP IV"). Three Arch Management IV, L.L.C. ("TAM IV"), the general partner of TAP IV, has sole voting and dispositive power with respect to the securities held by TAP IV. Mark A. Wan and Wilfred E. Jaeger, the managing members of TAM IV, share the voting and dispositive power with respect to the shares held by TAP IV. Such persons and entities disclaim beneficial ownership of the shares held by TAP IV except to the extent of any pecuniary interest therein. Read SEC document
November 29, 2017 Filed Feb 14, 2020 17:58 UTC	NEVRO CORP NVRO · Entity 12422	OtherCommon Stock	1,021	$0.00	$0.00	Disclosure SEC source: 0001567619-20-004114 · doc1.xml · nonDerivative · entry 7 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,106 F1 · kind: Pro rata in-kind distribution from Three Arch Management IV, LLC for no consideration. F5 · ownership.nature: Shares are held by Emma Louise Jaeger 2002 Irrevocable Trust U/D/T 04/23/2002. Read SEC document
November 29, 2017 Filed Feb 14, 2020 17:58 UTC	NEVRO CORP NVRO · Entity 12422	OtherCommon Stock	1,021	$0.00	$0.00	Disclosure SEC source: 0001567619-20-004114 · doc1.xml · nonDerivative · entry 5 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,106 F1 · kind: Pro rata in-kind distribution from Three Arch Management IV, LLC for no consideration. F4 · ownership.nature: Shares are held by Nicholas Graham Jaeger 2002 Irrevocable Trust U/D/T 04/23/2002. Read SEC document
November 29, 2017 Filed Feb 14, 2020 17:58 UTC	NEVRO CORP NVRO · Entity 12422	OtherCommon Stock	349	$0.00	$0.00	Disclosure SEC source: 0001567619-20-004114 · doc1.xml · nonDerivative · entry 2 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 25,341 F2 · kind: Pro rata in-kind distribution from Three Arch Associates IV, LP for no consideration. F3 · ownership.nature: Shares are held by Wilfred E. Jaeger and Judith F. Jaeger, TTEES of the Jaeger Family Trust DTD 4/30/99. Read SEC document
November 29, 2017 Filed Feb 14, 2020 17:58 UTC	NEVRO CORP NVRO · Entity 12422	OtherCommon Stock	7,976	$0.00	$0.00	Disclosure SEC source: 0001567619-20-004114 · doc1.xml · nonDerivative · entry 1 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 25,341 F1 · kind: Pro rata in-kind distribution from Three Arch Management IV, LLC for no consideration. F3 · ownership.nature: Shares are held by Wilfred E. Jaeger and Judith F. Jaeger, TTEES of the Jaeger Family Trust DTD 4/30/99. Read SEC document
September 14, 2017 Filed Sep 18, 2017 18:58 UTC	NEVRO CORP NVRO · Entity 12422	SaleCommon Stock	286	$90.31	$25,828.72	Disclosure SEC source: 0001209191-17-053221 · doc4.xml · nonDerivative · entry 4 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 20,764 F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $90.01 to $90.825, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: Shares are held by Three Arch Associates IV, L.P. ("TAA IV"). TAM IV, the general partner of TAA IV, has sole voting and dispositive power with respect to the securities held by TAA IV. Mark A. Wan and Wilfred E. Jaeger, the managing members of TAM IV, share the voting and dispositive power with respect to the shares held by TAA IV. Such persons and entities disclaim beneficial ownership of the shares held by TAA IV except to the extent of any pecuniary interest therein. Read SEC document
September 14, 2017 Filed Sep 18, 2017 18:58 UTC	NEVRO CORP NVRO · Entity 12422	SaleCommon Stock	12,935	$90.31	$1,168,162.44	Disclosure SEC source: 0001209191-17-053221 · doc4.xml · nonDerivative · entry 3 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 940,387 F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $90.01 to $90.825, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · ownership.nature: Shares are held by Three Arch Partners IV, L.P. ("TAP IV"). Three Arch Management IV, L.L.C. ("TAM IV"), the general partner of TAP IV, has sole voting and dispositive power with respect to the securities held by TAP IV. Mark A. Wan and Wilfred E. Jaeger, the managing members of TAM IV, share the voting and dispositive power with respect to the shares held by TAP IV. Such persons and entities disclaim beneficial ownership of the shares held by TAP IV except to the extent of any pecuniary interest therein. Read SEC document
September 14, 2017 Filed Sep 18, 2017 18:58 UTC	NEVRO CORP NVRO · Entity 12422	SaleCommon Stock	70	$89.72	$6,280.06	Disclosure SEC source: 0001209191-17-053221 · doc4.xml · nonDerivative · entry 2 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 21,050 F1 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $89.00 to $90.00, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: Shares are held by Three Arch Associates IV, L.P. ("TAA IV"). TAM IV, the general partner of TAA IV, has sole voting and dispositive power with respect to the securities held by TAA IV. Mark A. Wan and Wilfred E. Jaeger, the managing members of TAM IV, share the voting and dispositive power with respect to the shares held by TAA IV. Such persons and entities disclaim beneficial ownership of the shares held by TAA IV except to the extent of any pecuniary interest therein. Read SEC document
September 14, 2017 Filed Sep 18, 2017 18:58 UTC	NEVRO CORP NVRO · Entity 12422	SaleCommon Stock	3,176	$89.72	$284,935.16	Disclosure SEC source: 0001209191-17-053221 · doc4.xml · nonDerivative · entry 1 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 953,322 F1 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $89.00 to $90.00, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · ownership.nature: Shares are held by Three Arch Partners IV, L.P. ("TAP IV"). Three Arch Management IV, L.L.C. ("TAM IV"), the general partner of TAP IV, has sole voting and dispositive power with respect to the securities held by TAP IV. Mark A. Wan and Wilfred E. Jaeger, the managing members of TAM IV, share the voting and dispositive power with respect to the shares held by TAP IV. Such persons and entities disclaim beneficial ownership of the shares held by TAP IV except to the extent of any pecuniary interest therein. Read SEC document
August 24, 2017 Filed Aug 24, 2017 20:15 UTC	NEVRO CORP NVRO · Entity 12422	SaleCommon Stock	158	$87.00	$13,746.00	Disclosure SEC source: 0001209191-17-050230 · doc4.xml · nonDerivative · entry 8 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 21,120 F3 · ownership.nature: Shares are held by Three Arch Associates IV, L.P. ("TAA IV"). TAM IV, the general partner of TAA IV, has sole voting and dispositive power with respect to the securities held by TAA IV. Mark A. Wan and Wilfred E. Jaeger, the managing members of TAM IV, share the voting and dispositive power with respect to the shares held by TAA IV. Such persons and entities disclaim beneficial ownership of the shares held by TAA IV except to the extent of any pecuniary interest therein. Read SEC document
August 24, 2017 Filed Aug 24, 2017 20:15 UTC	NEVRO CORP NVRO · Entity 12422	SaleCommon Stock	7,156	$87.00	$622,572.00	Disclosure SEC source: 0001209191-17-050230 · doc4.xml · nonDerivative · entry 7 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 956,498 F2 · ownership.nature: Shares are held by Three Arch Partners IV, L.P. ("TAP IV"). Three Arch Management IV, L.L.C. ("TAM IV"), the general partner of TAP IV, has sole voting and dispositive power with respect to the securities held by TAP IV. Mark A. Wan and Wilfred E. Jaeger, the managing members of TAM IV, share the voting and dispositive power with respect to the shares held by TAP IV. Such persons and entities disclaim beneficial ownership of the shares held by TAP IV except to the extent of any pecuniary interest therein. Read SEC document
August 23, 2017 Filed Aug 24, 2017 20:15 UTC	NEVRO CORP NVRO · Entity 12422	SaleCommon Stock	112	$87.01	$9,745.30	Disclosure SEC source: 0001209191-17-050230 · doc4.xml · nonDerivative · entry 6 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 21,278 F5 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $87.00 to $87.16, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: Shares are held by Three Arch Associates IV, L.P. ("TAA IV"). TAM IV, the general partner of TAA IV, has sole voting and dispositive power with respect to the securities held by TAA IV. Mark A. Wan and Wilfred E. Jaeger, the managing members of TAM IV, share the voting and dispositive power with respect to the shares held by TAA IV. Such persons and entities disclaim beneficial ownership of the shares held by TAA IV except to the extent of any pecuniary interest therein. Read SEC document
August 23, 2017 Filed Aug 24, 2017 20:15 UTC	NEVRO CORP NVRO · Entity 12422	SaleCommon Stock	5,094	$87.01	$443,237.09	Disclosure SEC source: 0001209191-17-050230 · doc4.xml · nonDerivative · entry 5 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 963,654 F5 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $87.00 to $87.16, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · ownership.nature: Shares are held by Three Arch Partners IV, L.P. ("TAP IV"). Three Arch Management IV, L.L.C. ("TAM IV"), the general partner of TAP IV, has sole voting and dispositive power with respect to the securities held by TAP IV. Mark A. Wan and Wilfred E. Jaeger, the managing members of TAM IV, share the voting and dispositive power with respect to the shares held by TAP IV. Such persons and entities disclaim beneficial ownership of the shares held by TAP IV except to the extent of any pecuniary interest therein. Read SEC document
August 22, 2017 Filed Aug 24, 2017 20:15 UTC	NEVRO CORP NVRO · Entity 12422	SaleCommon Stock	432	$86.48	$37,359.62	Disclosure SEC source: 0001209191-17-050230 · doc4.xml · nonDerivative · entry 4 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 21,390 F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $86.00 to $86.99, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: Shares are held by Three Arch Associates IV, L.P. ("TAA IV"). TAM IV, the general partner of TAA IV, has sole voting and dispositive power with respect to the securities held by TAA IV. Mark A. Wan and Wilfred E. Jaeger, the managing members of TAM IV, share the voting and dispositive power with respect to the shares held by TAA IV. Such persons and entities disclaim beneficial ownership of the shares held by TAA IV except to the extent of any pecuniary interest therein. Read SEC document
August 22, 2017 Filed Aug 24, 2017 20:15 UTC	NEVRO CORP NVRO · Entity 12422	SaleCommon Stock	19,568	$86.48	$1,692,252.38	Disclosure SEC source: 0001209191-17-050230 · doc4.xml · nonDerivative · entry 3 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 968,748 F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $86.00 to $86.99, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · ownership.nature: Shares are held by Three Arch Partners IV, L.P. ("TAP IV"). Three Arch Management IV, L.L.C. ("TAM IV"), the general partner of TAP IV, has sole voting and dispositive power with respect to the securities held by TAP IV. Mark A. Wan and Wilfred E. Jaeger, the managing members of TAM IV, share the voting and dispositive power with respect to the shares held by TAP IV. Such persons and entities disclaim beneficial ownership of the shares held by TAP IV except to the extent of any pecuniary interest therein. Read SEC document
August 22, 2017 Filed Aug 24, 2017 20:15 UTC	NEVRO CORP NVRO · Entity 12422	SaleCommon Stock	432	$85.17	$36,794.82	Disclosure SEC source: 0001209191-17-050230 · doc4.xml · nonDerivative · entry 2 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 21,822 F1 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $85.00 to $85.62, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: Shares are held by Three Arch Associates IV, L.P. ("TAA IV"). TAM IV, the general partner of TAA IV, has sole voting and dispositive power with respect to the securities held by TAA IV. Mark A. Wan and Wilfred E. Jaeger, the managing members of TAM IV, share the voting and dispositive power with respect to the shares held by TAA IV. Such persons and entities disclaim beneficial ownership of the shares held by TAA IV except to the extent of any pecuniary interest therein. Read SEC document
August 22, 2017 Filed Aug 24, 2017 20:15 UTC	NEVRO CORP NVRO · Entity 12422	SaleCommon Stock	19,568	$85.17	$1,666,669.18	Disclosure SEC source: 0001209191-17-050230 · doc4.xml · nonDerivative · entry 1 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 988,316 F1 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $85.00 to $85.62, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · ownership.nature: Shares are held by Three Arch Partners IV, L.P. ("TAP IV"). Three Arch Management IV, L.L.C. ("TAM IV"), the general partner of TAP IV, has sole voting and dispositive power with respect to the securities held by TAP IV. Mark A. Wan and Wilfred E. Jaeger, the managing members of TAM IV, share the voting and dispositive power with respect to the shares held by TAP IV. Such persons and entities disclaim beneficial ownership of the shares held by TAP IV except to the extent of any pecuniary interest therein. Read SEC document
August 21, 2017 Filed Aug 21, 2017 18:53 UTC	NEVRO CORP NVRO · Entity 12422	SaleCommon Stock	540	$84.44	$45,600.03	Disclosure SEC source: 0001209191-17-049758 · doc4.xml · nonDerivative · entry 4 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 22,254 F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $84.225 to $84.520, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: Shares are held by Three Arch Associates IV, L.P. ("TAA IV"). TAM IV, the general partner of TAA IV, has sole voting and dispositive power with respect to the securities held by TAA IV. Mark A. Wan and Wilfred E. Jaeger, the managing members of TAM IV, share the voting and dispositive power with respect to the shares held by TAA IV. Such persons and entities disclaim beneficial ownership of the shares held by TAA IV except to the extent of any pecuniary interest therein. Read SEC document
August 21, 2017 Filed Aug 21, 2017 18:53 UTC	NEVRO CORP NVRO · Entity 12422	SaleCommon Stock	24,460	$84.44	$2,065,512.47	Disclosure SEC source: 0001209191-17-049758 · doc4.xml · nonDerivative · entry 3 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,007,884 F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $84.225 to $84.520, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · ownership.nature: Shares are held by Three Arch Partners IV, L.P. ("TAP IV"). Three Arch Management IV, L.L.C. ("TAM IV"), the general partner of TAP IV, has sole voting and dispositive power with respect to the securities held by TAP IV. Mark A. Wan and Wilfred E. Jaeger, the managing members of TAM IV, share the voting and dispositive power with respect to the shares held by TAP IV. Such persons and entities disclaim beneficial ownership of the shares held by TAP IV except to the extent of any pecuniary interest therein. Read SEC document
August 17, 2017 Filed Aug 21, 2017 18:53 UTC	NEVRO CORP NVRO · Entity 12422	SaleCommon Stock	331	$84.02	$27,810.22	Disclosure SEC source: 0001209191-17-049758 · doc4.xml · nonDerivative · entry 2 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 22,794 F1 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $84.000 to $84.125, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: Shares are held by Three Arch Associates IV, L.P. ("TAA IV"). TAM IV, the general partner of TAA IV, has sole voting and dispositive power with respect to the securities held by TAA IV. Mark A. Wan and Wilfred E. Jaeger, the managing members of TAM IV, share the voting and dispositive power with respect to the shares held by TAA IV. Such persons and entities disclaim beneficial ownership of the shares held by TAA IV except to the extent of any pecuniary interest therein. Read SEC document
August 17, 2017 Filed Aug 21, 2017 18:53 UTC	NEVRO CORP NVRO · Entity 12422	SaleCommon Stock	15,012	$84.02	$1,261,290.23	Disclosure SEC source: 0001209191-17-049758 · doc4.xml · nonDerivative · entry 1 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,032,344 F1 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $84.000 to $84.125, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · ownership.nature: Shares are held by Three Arch Partners IV, L.P. ("TAP IV"). Three Arch Management IV, L.L.C. ("TAM IV"), the general partner of TAP IV, has sole voting and dispositive power with respect to the securities held by TAP IV. Mark A. Wan and Wilfred E. Jaeger, the managing members of TAM IV, share the voting and dispositive power with respect to the shares held by TAP IV. Such persons and entities disclaim beneficial ownership of the shares held by TAP IV except to the extent of any pecuniary interest therein. Read SEC document
August 16, 2017 Filed Aug 16, 2017 18:42 UTC	NEVRO CORP NVRO · Entity 12422	SaleCommon Stock	236	$84.04	$19,833.82	Disclosure SEC source: 0001209191-17-049282 · doc4.xml · nonDerivative · entry 8 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 23,125 F6 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $83.71 to $84.25, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: Shares are held by Three Arch Associates IV, L.P. ("TAA IV"). TAM IV, the general partner of TAA IV, has sole voting and dispositive power with respect to the securities held by TAA IV. Mark A. Wan and Wilfred E. Jaeger, the managing members of TAM IV, share the voting and dispositive power with respect to the shares held by TAA IV. Such persons and entities disclaim beneficial ownership of the shares held by TAA IV except to the extent of any pecuniary interest therein. Read SEC document
August 16, 2017 Filed Aug 16, 2017 18:42 UTC	NEVRO CORP NVRO · Entity 12422	SaleCommon Stock	10,701	$84.04	$899,329.16	Disclosure SEC source: 0001209191-17-049282 · doc4.xml · nonDerivative · entry 7 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,047,356 F6 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $83.71 to $84.25, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · ownership.nature: Shares are held by Three Arch Partners IV, L.P. ("TAP IV"). Three Arch Management IV, L.L.C. ("TAM IV"), the general partner of TAP IV, has sole voting and dispositive power with respect to the securities held by TAP IV. Mark A. Wan and Wilfred E. Jaeger, the managing members of TAM IV, share the voting and dispositive power with respect to the shares held by TAP IV. Such persons and entities disclaim beneficial ownership of the shares held by TAP IV except to the extent of any pecuniary interest therein. Read SEC document
August 16, 2017 Filed Aug 16, 2017 18:42 UTC	NEVRO CORP NVRO · Entity 12422	SaleCommon Stock	299	$82.75	$24,742.67	Disclosure SEC source: 0001209191-17-049282 · doc4.xml · nonDerivative · entry 6 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 23,361 F5 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $82.55 to $83.45, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: Shares are held by Three Arch Associates IV, L.P. ("TAA IV"). TAM IV, the general partner of TAA IV, has sole voting and dispositive power with respect to the securities held by TAA IV. Mark A. Wan and Wilfred E. Jaeger, the managing members of TAM IV, share the voting and dispositive power with respect to the shares held by TAA IV. Such persons and entities disclaim beneficial ownership of the shares held by TAA IV except to the extent of any pecuniary interest therein. Read SEC document
August 16, 2017 Filed Aug 16, 2017 18:42 UTC	NEVRO CORP NVRO · Entity 12422	SaleCommon Stock	13,501	$82.75	$1,117,226.65	Disclosure SEC source: 0001209191-17-049282 · doc4.xml · nonDerivative · entry 5 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,058,057 F5 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $82.55 to $83.45, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · ownership.nature: Shares are held by Three Arch Partners IV, L.P. ("TAP IV"). Three Arch Management IV, L.L.C. ("TAM IV"), the general partner of TAP IV, has sole voting and dispositive power with respect to the securities held by TAP IV. Mark A. Wan and Wilfred E. Jaeger, the managing members of TAM IV, share the voting and dispositive power with respect to the shares held by TAP IV. Such persons and entities disclaim beneficial ownership of the shares held by TAP IV except to the extent of any pecuniary interest therein. Read SEC document
August 15, 2017 Filed Aug 16, 2017 18:42 UTC	NEVRO CORP NVRO · Entity 12422	SaleCommon Stock	641	$82.54	$52,905.45	Disclosure SEC source: 0001209191-17-049282 · doc4.xml · nonDerivative · entry 4 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 23,660 F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $82.30 to $82.85, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: Shares are held by Three Arch Associates IV, L.P. ("TAA IV"). TAM IV, the general partner of TAA IV, has sole voting and dispositive power with respect to the securities held by TAA IV. Mark A. Wan and Wilfred E. Jaeger, the managing members of TAM IV, share the voting and dispositive power with respect to the shares held by TAA IV. Such persons and entities disclaim beneficial ownership of the shares held by TAA IV except to the extent of any pecuniary interest therein. Read SEC document
August 15, 2017 Filed Aug 16, 2017 18:42 UTC	NEVRO CORP NVRO · Entity 12422	SaleCommon Stock	29,024	$82.54	$2,395,519.06	Disclosure SEC source: 0001209191-17-049282 · doc4.xml · nonDerivative · entry 3 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,071,558 F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $82.30 to $82.85, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · ownership.nature: Shares are held by Three Arch Partners IV, L.P. ("TAP IV"). Three Arch Management IV, L.L.C. ("TAM IV"), the general partner of TAP IV, has sole voting and dispositive power with respect to the securities held by TAP IV. Mark A. Wan and Wilfred E. Jaeger, the managing members of TAM IV, share the voting and dispositive power with respect to the shares held by TAP IV. Such persons and entities disclaim beneficial ownership of the shares held by TAP IV except to the extent of any pecuniary interest therein. Read SEC document
August 14, 2017 Filed Aug 16, 2017 18:42 UTC	NEVRO CORP NVRO · Entity 12422	SaleCommon Stock	546	$82.40	$44,990.51	Disclosure SEC source: 0001209191-17-049282 · doc4.xml · nonDerivative · entry 2 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 24,301 F1 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $82.30 to $82.60, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: Shares are held by Three Arch Associates IV, L.P. ("TAA IV"). TAM IV, the general partner of TAA IV, has sole voting and dispositive power with respect to the securities held by TAA IV. Mark A. Wan and Wilfred E. Jaeger, the managing members of TAM IV, share the voting and dispositive power with respect to the shares held by TAA IV. Such persons and entities disclaim beneficial ownership of the shares held by TAA IV except to the extent of any pecuniary interest therein. Read SEC document
August 14, 2017 Filed Aug 16, 2017 18:42 UTC	NEVRO CORP NVRO · Entity 12422	SaleCommon Stock	24,709	$82.40	$2,036,026.54	Disclosure SEC source: 0001209191-17-049282 · doc4.xml · nonDerivative · entry 1 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,100,582 F1 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $82.30 to $82.60, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · ownership.nature: Shares are held by Three Arch Partners IV, L.P. ("TAP IV"). Three Arch Management IV, L.L.C. ("TAM IV"), the general partner of TAP IV, has sole voting and dispositive power with respect to the securities held by TAP IV. Mark A. Wan and Wilfred E. Jaeger, the managing members of TAM IV, share the voting and dispositive power with respect to the shares held by TAP IV. Such persons and entities disclaim beneficial ownership of the shares held by TAP IV except to the extent of any pecuniary interest therein. Read SEC document
June 15, 2017 Filed Jun 19, 2017 07:30 UTC	CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906	GrantNonstatutory Stock Option (right to buy) · Derivative	10,000	$0.00 Strike: $13.29	$0.00	Disclosure SEC source: 0001209191-17-040707 · doc4.xml · derivative · entry 1 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-06-14 F1 · derivative.exercise_date: The shares underlying this option vest in equal quarterly installments over a one-year period, through and including June 15, 2018. Read SEC document
May 25, 2017 Filed May 30, 2017 18:53 UTC	NEVRO CORP NVRO · Entity 12422	GrantStock Option (Right to Buy) · Derivative	3,545	$0.00 Strike: $74.07	$0.00	Disclosure SEC source: 0001140361-17-022921 · doc1.xml · derivative · entry 4 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,545 Underlying: Common Stock · 3,545 shares Expires 2027-05-24 F5 · derivative.exercise_date: 1/12th of the shares subject to the option vest on each monthly anniversary measured from May 25, 2017 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the first anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the issuer. Read SEC document
May 25, 2017 Filed May 30, 2017 18:53 UTC	NEVRO CORP NVRO · Entity 12422	GrantCommon Stock	1,518	$0.00	$0.00	Disclosure SEC source: 0001140361-17-022921 · doc1.xml · nonDerivative · entry 1 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,518 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the one year anniversary of May 25, 2017, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 1,518 RSUs. Read SEC document
March 03, 2017 Filed Mar 3, 2017 17:33 UTC	NEVRO CORP NVRO · Entity 12422	SaleCommon Stock	16	$95.00	$1,520.00	Disclosure SEC source: 0001209191-17-017808 · doc4.xml · nonDerivative · entry 6 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 24,847 F5 · price: The shares were sold in multiple transactions, each at a price of $95.00. F3 · ownership.nature: Shares are held by Three Arch Associates IV, L.P. ("TAA IV"). TAM IV, the general partner of TAA IV, has sole voting and dispositive power with respect to the securities held by TAA IV. Mark A. Wan and Wilfred E. Jaeger, the managing members of TAM IV, share the voting and dispositive power with respect to the shares held by TAA IV. Such persons and entities disclaim beneficial ownership of the shares held by TAA IV except to the extent of any pecuniary interest therein. Read SEC document
March 03, 2017 Filed Mar 3, 2017 17:33 UTC	NEVRO CORP NVRO · Entity 12422	SaleCommon Stock	703	$95.00	$66,785.00	Disclosure SEC source: 0001209191-17-017808 · doc4.xml · nonDerivative · entry 5 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,125,291 F5 · price: The shares were sold in multiple transactions, each at a price of $95.00. F2 · ownership.nature: Shares are held by Three Arch Partners IV, L.P. ("TAP IV"). Three Arch Management IV, L.L.C. ("TAM IV"), the general partner of TAP IV, has sole voting and dispositive power with respect to the securities held by TAP IV. Mark A. Wan and Wilfred E. Jaeger, the managing members of TAM IV, share the voting and dispositive power with respect to the shares held by TAP IV. Such persons and entities disclaim beneficial ownership of the shares held by TAP IV except to the extent of any pecuniary interest therein. Read SEC document
March 02, 2017 Filed Mar 3, 2017 17:33 UTC	NEVRO CORP NVRO · Entity 12422	SaleCommon Stock	6	$95.00	$570.00	Disclosure SEC source: 0001209191-17-017808 · doc4.xml · nonDerivative · entry 4 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 24,863 F4 · price: The shares were sold in a single transaction at a price of $95.00. F3 · ownership.nature: Shares are held by Three Arch Associates IV, L.P. ("TAA IV"). TAM IV, the general partner of TAA IV, has sole voting and dispositive power with respect to the securities held by TAA IV. Mark A. Wan and Wilfred E. Jaeger, the managing members of TAM IV, share the voting and dispositive power with respect to the shares held by TAA IV. Such persons and entities disclaim beneficial ownership of the shares held by TAA IV except to the extent of any pecuniary interest therein. Read SEC document
March 02, 2017 Filed Mar 3, 2017 17:33 UTC	NEVRO CORP NVRO · Entity 12422	SaleCommon Stock	294	$95.00	$27,930.00	Disclosure SEC source: 0001209191-17-017808 · doc4.xml · nonDerivative · entry 3 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,125,994 F4 · price: The shares were sold in a single transaction at a price of $95.00. F2 · ownership.nature: Shares are held by Three Arch Partners IV, L.P. ("TAP IV"). Three Arch Management IV, L.L.C. ("TAM IV"), the general partner of TAP IV, has sole voting and dispositive power with respect to the securities held by TAP IV. Mark A. Wan and Wilfred E. Jaeger, the managing members of TAM IV, share the voting and dispositive power with respect to the shares held by TAP IV. Such persons and entities disclaim beneficial ownership of the shares held by TAP IV except to the extent of any pecuniary interest therein. Read SEC document
March 01, 2017 Filed Mar 3, 2017 17:33 UTC	NEVRO CORP NVRO · Entity 12422	SaleCommon Stock	928	$95.03	$88,190.90	Disclosure SEC source: 0001209191-17-017808 · doc4.xml · nonDerivative · entry 2 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 24,869 F1 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $95.00 to $95.12, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: Shares are held by Three Arch Associates IV, L.P. ("TAA IV"). TAM IV, the general partner of TAA IV, has sole voting and dispositive power with respect to the securities held by TAA IV. Mark A. Wan and Wilfred E. Jaeger, the managing members of TAM IV, share the voting and dispositive power with respect to the shares held by TAA IV. Such persons and entities disclaim beneficial ownership of the shares held by TAA IV except to the extent of any pecuniary interest therein. Read SEC document
March 01, 2017 Filed Mar 3, 2017 17:33 UTC	NEVRO CORP NVRO · Entity 12422	SaleCommon Stock	42,033	$95.03	$3,994,534.70	Disclosure SEC source: 0001209191-17-017808 · doc4.xml · nonDerivative · entry 1 JAEGER WILFRED E · CIK 0001190474 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,126,288 F1 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $95.00 to $95.12, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · ownership.nature: Shares are held by Three Arch Partners IV, L.P. ("TAP IV"). Three Arch Management IV, L.L.C. ("TAM IV"), the general partner of TAP IV, has sole voting and dispositive power with respect to the securities held by TAP IV. Mark A. Wan and Wilfred E. Jaeger, the managing members of TAM IV, share the voting and dispositive power with respect to the shares held by TAP IV. Such persons and entities disclaim beneficial ownership of the shares held by TAP IV except to the extent of any pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.